Moleculin Biotech, Inc. (MBRX) is a Houston-based, Phase 3 clinical-stage pharmaceutical company developing therapies for hard-to-treat cancers. Its lead asset, Annamycin (naxtarubicin), is a next-generation anthracycline engineered to avoid multidrug resistance and cardiotoxicity, and is being tested in the pivotal MIRACLE Phase 2/3 trial in relapsed or refractory acute myeloid leukemia. The company generates no product revenue.
In today's session, the stock climbed 10.67% to $7.47, compared with the previous completed session's close of $6.75 — a gain of $0.72. The direction was clearly upward, but no verified corporate announcement, filing, or analyst action published during the session accounted for the move.
No verified news or fundamental catalyst found explains today's gain. Moleculin's most recent disclosures — a Korean patent allowance announced Nov. 18, third-quarter results released Nov. 16, and an Australian patent grant announced Nov. 12 — were all published before today's session, and the stock actually declined on the two most recent of those days. A routine insider-sale disclosure covering a director's small share sale was also immaterial in size.
The price action is most consistent with a mechanical snap-back in an exceptionally thin security. The shares had printed four straight lower closes from Nov. 13 through Nov. 18, a cumulative decline of roughly 16% that left the stock near the bottom of its recent range. With only about 1.05 million shares outstanding following October's 1-for-20 reverse split, relatively small buy orders can move the quoted price by double-digit percentages. Today's intraday range of roughly $6.71 to $8.49 — a spread of more than 26% — is characteristic of a shallow order book rather than a fundamental re-rating.
Anything resembling a fundamental catalyst sits in the future, not in today's tape.
Third-quarter results, reported Nov. 16, showed a net loss of about $6.5 million, narrowed from $25.4 million a year earlier largely because of a prior-year non-cash warrant charge. Operating losses actually widened to $6.6 million as MIRACLE-related research spending rose, and cash and equivalents slipped to $7.3 million from $8.9 million at the end of 2025, against $21.7 million of operating cash burn over nine months. The company has said it will need significant additional financing.
Operationally, the picture was more constructive: all 90 patients in Part A of the MIRACLE trial have completed treatment, with comprehensive data guided for the first quarter of 2027. Patent allowances in Korea and Australia extend formulation and reconstitution protection across more than 20 jurisdictions, but these are routine milestones that have historically produced only modest, short-lived share-price reactions.
Volume was clearly elevated. Roughly 69,000 shares had changed hands by early afternoon, well above the 60-day average of about 27,000 shares, and turnover of more than half a million dollars is notable for a company with a market capitalization near $7.8 million. Even so, that dollar volume is trivial in absolute terms, which is precisely why the percentage move looks large.
The advance was not mirrored across clinical-stage oncology peers or broad biotech benchmarks, and there was no consistent sector-wide bid to point to. Technically, the rebound lifted the stock off the lows but stalled below its 20-day average near $7.90, and the intraday push toward $8.49 faded — a pattern suggesting short-covering and opportunistic buying rather than sustained accumulation. The stock remains far below its levels of earlier this year.
The score runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news paired with an extreme, rare price move. Moleculin's score is 17 out of 100.
Verified news strength was weak: today brought no announcement at all, and the prior week's patent allowances and quarterly results were routine for a company of this size and had already been absorbed by the market. The move was also only about 1.7 times the stock's typical absolute daily change of roughly 6.2%, and moves of 10.7% or more have occurred six times in the past 60 sessions. A large but familiar swing in a thinly traded micro-cap therefore combines with negligible news to produce a low score.
The dominant scheduled event is the presentation of interim MIRACLE trial data at a major hematology meeting in December, followed by the comprehensive Part A readout guided for the first quarter of 2027, which will inform optimal dose selection and the start of Part B. Investors will also watch for any announcement regarding capital raising, given the company's cash position and its own disclosure that substantial additional funding is required. Analyst coverage is sparse, with a small number of firms publishing estimates, so single rating changes can move sentiment disproportionately. Sector developments in acute myeloid leukemia therapies and any investigator-sponsored pancreatic cancer work are secondary catalysts. Key risks include dilution from future equity issuance, trial delays, binary clinical outcomes, and the potential for continued Nasdaq listing pressure.
Tickeron's Trending AI Robots page curates the strongest performing automated strategies under current market conditions from a library of hundreds of AI trading bots spanning thousands of tickers. Because bots differ widely by strategy logic, holding timeframe, performance metrics, and the specific symbols they trade, the featured list changes as market conditions shift. It offers a practical starting point for traders comparing systematic approaches rather than relying on a single signal.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 256 similar instances where the Aroon Indicator formed such a pattern. In 233 of the 256 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBRX as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBRX's RSI Oscillator exited the oversold zone, 40 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on November 19, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. MBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.306) is normal, around the industry mean (3.596). P/E Ratio (0.596) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
Industry Biotechnology